Trial Status:
Open to Enrollment
Trial Eligibility:
Inclusion Criteria:
- Ability to provide signed informed consent (with or without Legal authorized representative, as appropriate) and willingness to comply with protocol requirements
- Male or female 60-90 years of age
- Documentation of clinical diagnosis of one or more of the following: subjective memory complaints, mild cognitive impairment, Alzheimer’s Disease
Exclusion Criteria:
- A questionnaire-based screen reveals confounding neurological disease, or the MRI over-read by staff radiologists reveals the same
- Neurological co-morbidities unrelated to neurodegeneration, including, but not limited to stroke, hydrocephalus or epilepsy
- Gene variation that would inhibit binding to study drug (DPA713) and/or clinical factors that would compromise statistical analysis of the PET
- Any metal in the body above the waist, claustrophobia, unlikely to remain still during examinations or other contraindication for MRI (i.e. ferromagnetic implants, pace-maker, etc.)
- Other unspecified reasons that, in the opinion of investigators, make the subject unsuitable for enrollment
Trial Description:
The purpose of this study is to investigate the relationships between neuroinflammation and Alzheimer’s disease (AD). Neuroinflammation is inflammation that occurs in the brain. Certain cells in the brain called microglia are involved in regulating inflammation. The accumulation of certain abnormal proteins, such as tau, have been implicated in AD. Tau may promote inflammatory reactions by microglial cells.
We think that measuring the activity of microglia cells with experimental imaging techniques might be able to help us better understand the extent to which neuroinflammation is involved in the progression of AD.
Primary Investigator:
Tracy A. Butler, MD
Trial Location:
Upper East Side - Manhattan
Drugs / Device:
na
Protocol ID:
1906020377
Study Type:
Observational
Sponsor:
National Institutes of Health (NIH)
Trial Category:
Alzheimer's Disease Neurological Disorders